Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Trastuzumab 3Docetaxel 3Biopsy 3trastuzumab deruxtecan 2pembrolizumab 2Vorinostat 2Taxes 2SS1(dsFv)PE38 2Polymerase Chain Reaction 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Gene Expression Profiling 2Flow Cytometry 2zanidatamab 1tipifarnib 1tanespimycin 1spartalizumab 1sargramostim 1pertuzumab 1oncogene protein E7, Human papillomavirus type 16 1neratinib 1entrectinib 1entinostat 1ceralasertib 1alectinib 1aldesleukin 1Specimen Handling 1Ritonavir 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × zanidatamab × Gynecologic × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡